Phase II trial of fludarabine alternating with interferon (IFN)alpha 2B in low grade non-Hodgkin's lymphoma (NHL)

被引：0
|
作者：
Smith, MR
Boyd, RL
Minnitti, C
Clyde, J
Hoessly, MC
Cornfeld, M
Yeslow, G
Halbherr, T
Rogatko, A
Schilder, RJ
Young, RC
Millenson, MM
机构：
[1] FOX CHASE CANC CTR,PHILADELPHIA,PA 19111
[2] FOX CHASE NETWORK,PHILADELPHIA,PA 19111
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：861 / 861
页数：1
相关论文
共 50 条
  • [21] Comparitive economic analysis of the treatment of relapsed low grade B cell non-Hodgkin's lymphoma (NHL) using CHOP, fludarabine or rituximab.
    Sweetenham, J
    McIntyre, AM
    Howard, P
    Smartt, P
    Kerrigan, M
    Townshend, S
    Hieke, K
    BLOOD, 1998, 92 (10) : 415A - 415A
  • [22] Daunoxome in the treatment of relapsed/refractory low grade and intermediate grade non-Hodgkin's lymphoma (NHL)
    Tulpule, A
    Rarick, MU
    Kolitz, J
    Bernstein, J
    HarveyBuchanan, L
    Espina, BM
    Trader, G
    Mukwaya, G
    Onetto, N
    Gill, PS
    Levine, AM
    BLOOD, 1997, 90 (10) : 846 - 846
  • [23] Fludarabine monophosphate followed by iodine I 131 tositumomab for untreated low-grade and follicular non-Hodgkin's lymphoma (NHL).
    Leonard, JP
    Coleman, M
    Kostakoglu, L
    Chadburn, A
    Cesarman, E
    Bhatnagar, A
    Tidmarsh, GF
    Kroll, SM
    Goldsmith, SJ
    BLOOD, 1999, 94 (10) : 90A - 90A
  • [24] Safety and efficacy of fludarabine and mitoxantrone with rituximab consolidation in untreated advanced low grade non-Hodgkin's lymphoma (LG-NHL).
    Gregory, SA
    Venugopal, P
    Adler, SS
    O'Brien, TM
    O'Donnell, KF
    Yunus, F
    BLOOD, 2001, 98 (11) : 605A - 605A
  • [25] Phase I/II Trial of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)
    Kallam, Avyakta
    Meza, Jane
    Bierman, Philip
    Lunning, Matthew A.
    Bociek, R. Gregory
    Armitage, James Olen
    Vose, Julie M.
    BLOOD, 2017, 130
  • [26] Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)
    Ishizawa, Kenichi
    Tobinai, Kensei
    Ogura, Michinori
    Itoh, Kuniaki
    Aorishima, Yasuo
    Ando, Kiyoshi
    Yamamoto, Joji
    Watanabe, Takashi
    Uchida, Toshiki
    Nakata, Masanobu
    Hayashi, Masaki
    Hotta, Tomomitsu
    BLOOD, 2007, 110 (11) : 387A - 387A
  • [27] Phase II study of combination therapy with CHOP Interferon (IFN) alpha and rituximab (R) in chemo-naive patients (pts) with diffuse large B cell non-Hodgkin's lymphoma (NHL).
    Rapoport, BL
    Slabber, CF
    Cohen, G
    McMichael, G
    Alberts, AS
    Vorobiof, DA
    Uys, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 608S - 608S
  • [28] Phase 2 multicenter trial of gallium nitrate in patients with advanced non-Hodgkin's lymphoma (NHL).
    Pro, B
    Bociek, RG
    Chitambar, CR
    Gregory, SA
    Leonard, JP
    Smith, S
    Novick, S
    BLOOD, 2004, 104 (11) : 682A - 682A
  • [29] Phase II trial of Doxil® in patients with refractory/relapsed low-grade non-Hodgkin's lymphoma.
    Di Bella, NJ
    Khan, MM
    Dakhil, SR
    Logie, KW
    Marsland, TA
    Simon, SR
    Weinstein, RE
    BLOOD, 2000, 96 (11) : 236B - 236B
  • [30] Fludarabine-induced tumour lysis in low-grade non-Hodgkin's lymphoma
    Killick, S
    Mercieca, J
    Nandi, A
    Behrens, J
    CLINICAL AND LABORATORY HAEMATOLOGY, 1997, 19 (01): : 79 - 80
12345